Drug intelligence / Profile preview

BLS-M32

Development stage: Preclinical
Lead developer: MOA Life Plus
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

BLS-M32 is a therapeutic vaccine under preclinical development by MOA Life Plus. It is being investigated for the treatment of sarcopenia, a condition characterized by loss of muscle mass and function, typically associated with aging or certain diseases. The drug falls within the therapeutic area of nervous system diseases. As of April 2025, its highest global R&D status is preclinical and it has not yet entered clinical trials or received regulatory approval in any jurisdiction. Detailed information about its mechanism of action, molecular target(s), or specific modality beyond "therapeutic vaccine" has not been disclosed publicly[1][2].

Beyond the preview

Go deeper on BLS-M32.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLS-M32.

Explore the full profile